September 18, 2017
Article Info
September 17, 2017
DRESS: What does the emergency physician need to know?
Authors: Matthew Nemero, DO (Resident Physician, SAUSHEC) and Joshua Oliver, MD (EM Attending Physician, SAUSHEC) // Edited by: Alex Koyfman, MD (@EMHighAK) and Brit Long, MD (@long_brit)
Case
A 15-year-old male patient presents to your emergency department with his family complaining of a fever for 3 days and a rash that started on his face and chest that has been spreading for 3 days. Past medical history is significant for 3 ED visits in the past 90 days and a new diagnosis of epilepsy for which he recently started seeing a neurologist and was placed on phenytoin 3 weeks ago.
Vitals: HR 84, BP 122/74, RR 12, T 38.8 (101.8F), SpO2 99% RA
- On physical exam, you palpate enlarged and tender cervical and axillary lymph nodes.
- You note the generalized rash shown below. It does not involve the oral mucosa.
September 13, 2017
Bacterial d-amino acids suppress sinonasal innate immunity through sweet taste receptors in solitary chemosensory cells
Sci. Signal. Vol 10, Issue 495 05 September 2017
+ See all authors and affiliations
September 6, 2017
August 27, 2017
A survey on the perception of allergy specialists about the reimbursed grass pollen tablets for seasonal allergic rhinitis in Italy
Clinical and Molecular Allergy
RESEARCH
OPEN ACCESS
Abstract
Background
Sublingual immunotherapy (SLIT) is a feasible option to classical subcutaneous immunotherapy to treat respiratory allergy and is increasingly prescribed in Europe. However, the lack of reimbursement may limit its prescription. In 2015, the 5-grass pollen tablets was authorized by the European Medicine Agency to treat grass-pollen induced rhinitis and was approved in Italy for full reimbursement. We evaluated the opinions of allergy specialists after the availability of the reimbursed 5-grass pollen tablets.
August 26, 2017
The evolving role of tiotropium in asthma
REVIEW
Emma R McIvor,1 R Andrew McIvor2
1Queen’s University, Belfast, UK; 2Department of Medicine, McMaster University, Firestone Institute for Respiratory Health, Hamilton, Ontario, Canada
Abstract: Tiotropium is a long-acting muscarinic antagonist (LAMA) that exerts its bronchodilatory effect by blocking endogenous acetylcholine receptors in the airways. Its safety and efficacy are well established for the treatment of COPD, and it is now being recognized for its role in improving lung function and control in asthma. This review discusses the evolving role of tiotropium delivered by the Respimat® in patients across the range of asthma severities and ages, and provides an overview of safety and efficacy data.
1Queen’s University, Belfast, UK; 2Department of Medicine, McMaster University, Firestone Institute for Respiratory Health, Hamilton, Ontario, Canada
Abstract: Tiotropium is a long-acting muscarinic antagonist (LAMA) that exerts its bronchodilatory effect by blocking endogenous acetylcholine receptors in the airways. Its safety and efficacy are well established for the treatment of COPD, and it is now being recognized for its role in improving lung function and control in asthma. This review discusses the evolving role of tiotropium delivered by the Respimat® in patients across the range of asthma severities and ages, and provides an overview of safety and efficacy data.
August 25, 2017
Management of chronic spontaneous urticaria (CSU): a treat to target approach using a patient reported outcome
SHORT REPORT
OPEN ACCESS
© The Author(s) 2017
Abstract
Background
Treat-to-target therapy approaches are established for chronic diseases such as diabetes, hypertension, and more recently rheumatoid arthritis, resulting in improved patient outcomes. These approaches do not use patient reported outcomes (PRO) as targets of therapy. Chronic spontaneous urticaria (CSU), also called chronic idiopathic urticaria (CIU), is defined as recurrent urticaria of known and unknown cause, lasting more than 6 weeks. Treatment of CSU can be challenging. However, with the advent of proven therapies and validated instruments for measuring disease activity, the concept of treat-to-target (T2T) can be successfully applied to CSU. Herein, we propose a potential PRO therapeutic target and suggest a T2T approach for the management of patients with CSU.
Subscribe to:
Posts (Atom)